TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis

Cancer Immunology, Immunotherapy

Volumn 62, Issue 4, 2013, Pages 653-663

  Diao, Zhijuan ^a   Shi, Juan ^a   Zhu, Jieqing ^a   Yuan, Haiqin ^a   Ru, Qiang ^a   Liu, Shilian ^a   Liu, Yanxin ^a   Zheng, Dexian ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Apoptosis; CD4+CD25+Foxp3+ Treg; DR5; Liver cancer; TRAIL

Indexed keywords

RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CD4+ CD25+ FOXP3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ CD25- T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL KILLING; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HEPA 1-6 CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REPEATED DRUG DOSE; SPLEEN; SURVIVAL TIME; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; FEMALE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84877839164     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1370-x     Document Type: Article

References (33)

1. Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3:673-682
2. Ashkenazi A, Pai RC, Fong S et al (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162
3. Walczak H, Miller RE, Ariail K et al (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5:157-163
4. -/- mice. Nat Immunol 4:255-260
5. Diehl GE, Yue HH, Hsieh K et al (2004) TRAIL-R as a negative regulator of innate immune cell responses. Immunity 21:877-889
6. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ (2002) Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168:1356-1361
7. Grosse-Wilde A, Voloshanenko O, Bailey SL et al (2008) TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 118:100-110
8. Finnberg N, Klein-Szanto AJ, El-Deiry WS (2008) TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 118:111-123
9. Takeda K, Hayakawa Y, Smyth MJ et al (2001) Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat Med 7:94-100
10. Fanger NA, Maliszewski CR, Schooley K, Griffith TS (1999) Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 190:1155-1164
11. Liu S, Yu Y, Zhang M, Wang W, Cao X (2001) The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 166:5407-5415
12. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H (1999) Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J Exp Med 189:1451-1460
13. + immunoregulatory cells. J Immunol 167:1137-1140
14. Chen ML, Pittet MJ, Gorelik L et al (2005) Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc Natl Acad Sci 102(2):419-424
15. + T cells is IL-10-dependent and reversible. J Leukoc Biol 86:273-281
16. +T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res 13:4345-4354
17. Mellor AL, Munn DH (2004) IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4:762-774
18. + effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. J Neuroinflammation 9:41
19. Zimmer J, Andrès E, Hentges F (2008) NK cells and Treg cells: a fascinating dance cheek to cheek. Eur J Immunol 38:2942-2945
20. + regulatory T cells. J Immunol 175:4180-4183
21. Liyanage UK, Moore TT, Joo HG et al (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761
22. + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98:1089-1099
23. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543
24. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128-3133
25. + regulatory T cells. J Exp Med 202:885-891
26. Liu JY, Wu Y, Zhang XS et al (2007) Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother 56:1597-1604
27. + regulatory T cell function. Science 309:1380-1384
28. Manoukian G, Hagemeister F (2009) Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 9:1445-1451
29. + regulatory T cells are highly susceptible to CD95 ligand- but not to TCR-mediated cell death. J Immunol 175:32-36
30. + regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer. Cancer Res 67:1291-1298
31. + regulatory T cells. Endocrinology 150:2000-2007
32. Munn DH, Mellor AL (2006) The tumor-draining lymph node as an immune-privileged site. Immunol Rev 213:146-158
33. + regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res 14:1032-1040